Amgen Delivers Solid Q3 Sales, Little Insight On Key R&D Programs

Question Of Omecamtiv, Sotorasib Filing Plans Unanswered

Abstract mash line and point Question mark. Business illustration. Polygonal low poly
Amgen left questions unanswered regarding sotorasib, omecamtiv and tezepelumab

More from Earnings

More from Business